Delcath Systems Inc (DCTH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Delcath Systems Inc (DCTH) has a cash flow conversion efficiency ratio of 0.074x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($8.25 Million) by net assets ($111.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Delcath Systems Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Delcath Systems Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Delcath Systems Inc total liabilities for a breakdown of total debt and financial obligations.
Delcath Systems Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Delcath Systems Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mirbud SA
WAR:MRB
|
0.000x |
|
SEONGAN CO. Ltd
KO:011300
|
-0.019x |
|
Fastighets AB Trianon (publ)
ST:TRIAN-B
|
0.014x |
|
LUBAWA SA
WAR:LBW
|
0.058x |
|
Cahya Mata Sarawak Bhd
KLSE:2852
|
0.027x |
|
Bredband2 i Skandinavien AB
ST:BRE2
|
0.127x |
|
FuelCell Energy Inc
NASDAQ:FCEL
|
-0.032x |
|
Aeris Resources Ltd
AU:AIS
|
0.215x |
Annual Cash Flow Conversion Efficiency for Delcath Systems Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Delcath Systems Inc from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see DCTH market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $111.22 Million | $22.52 Million | 0.202x | +174.50% |
| 2024-12-31 | $68.75 Million | $-18.68 Million | -0.272x | +86.28% |
| 2023-12-31 | $15.78 Million | $-31.25 Million | -1.981x | -146.51% |
| 2022-12-31 | $-5.86 Million | $-24.95 Million | 4.258x | +325.17% |
| 2021-12-31 | $11.95 Million | $-22.60 Million | -1.891x | -82.59% |
| 2020-12-31 | $22.08 Million | $-22.87 Million | -1.036x | -127.80% |
| 2019-12-31 | $-6.36 Million | $-23.69 Million | 3.726x | +277.88% |
| 2018-12-31 | $-14.94 Million | $-14.73 Million | 0.986x | +104.34% |
| 2017-12-31 | $678.00K | $-15.40 Million | -22.711x | -338.09% |
| 2016-12-31 | $-1.49 Million | $-14.21 Million | 9.539x | +599.66% |
| 2015-12-31 | $8.60 Million | $-16.42 Million | -1.909x | -122.74% |
| 2014-12-31 | $18.14 Million | $-15.55 Million | -0.857x | +24.35% |
| 2013-12-31 | $30.10 Million | $-34.10 Million | -1.133x | +54.67% |
| 2012-12-31 | $20.01 Million | $-50.01 Million | -2.499x | -74.57% |
| 2011-12-31 | $26.10 Million | $-37.37 Million | -1.432x | -72.88% |
| 2010-12-31 | $29.08 Million | $-24.08 Million | -0.828x | -88.06% |
| 2009-12-31 | $23.76 Million | $-10.46 Million | -0.440x | +33.15% |
| 2008-12-31 | $10.21 Million | $-6.72 Million | -0.659x | -94.31% |
| 2007-12-31 | $16.43 Million | $-5.57 Million | -0.339x | +70.19% |
| 2006-12-31 | $8.09 Million | $-9.20 Million | -1.137x | -374.44% |
| 2005-12-31 | $12.60 Million | $-3.02 Million | -0.240x | +44.79% |
| 2004-12-31 | $6.79 Million | $-2.95 Million | -0.434x | +55.57% |
| 2003-12-31 | $2.17 Million | $-2.12 Million | -0.977x | +10.20% |
| 2002-12-31 | $1.64 Million | $-1.78 Million | -1.088x | -55.01% |
| 2001-12-31 | $3.23 Million | $-2.27 Million | -0.702x | -852.96% |
| 2000-12-31 | $4.91 Million | $-361.26K | -0.074x | +96.69% |
| 1999-12-31 | $490.00K | $-1.09 Million | -2.224x | -- |
About Delcath Systems Inc
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development… Read more